CN105412291B - The proheparin that relaxes is preparing the application in treatment diabetic neuropathy and complication medicine - Google Patents
The proheparin that relaxes is preparing the application in treatment diabetic neuropathy and complication medicine Download PDFInfo
- Publication number
- CN105412291B CN105412291B CN201510906503.XA CN201510906503A CN105412291B CN 105412291 B CN105412291 B CN 105412291B CN 201510906503 A CN201510906503 A CN 201510906503A CN 105412291 B CN105412291 B CN 105412291B
- Authority
- CN
- China
- Prior art keywords
- extract
- application
- diabetic neuropathy
- neuropathy
- easypro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000032131 Diabetic Neuropathies Diseases 0.000 title claims abstract description 13
- 239000003814 drug Substances 0.000 title claims abstract description 11
- 208000002249 Diabetes Complications Diseases 0.000 title description 2
- 206010012655 Diabetic complications Diseases 0.000 title description 2
- 239000000284 extract Substances 0.000 claims abstract description 25
- 208000019423 liver disease Diseases 0.000 claims abstract description 14
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 12
- 238000002360 preparation method Methods 0.000 claims abstract description 10
- 244000111489 Gardenia augusta Species 0.000 claims abstract description 9
- 235000018958 Gardenia augusta Nutrition 0.000 claims abstract description 9
- XDQITMCFPPPMBC-TUANDBMESA-N scutelloside Natural products OC[C@H]1O[C@@H](O[C@@H]2O[C@@H]3C[C@H]4[C@H](O)[C@@H](O)[C@@](O)(CO3)[C@@H]24)[C@H](O)[C@@H](O)[C@@H]1O XDQITMCFPPPMBC-TUANDBMESA-N 0.000 claims abstract description 9
- 241000334160 Isatis Species 0.000 claims abstract description 7
- 208000033808 peripheral neuropathy Diseases 0.000 claims abstract description 5
- 201000001119 neuropathy Diseases 0.000 claims abstract description 4
- 230000007823 neuropathy Effects 0.000 claims abstract description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 18
- 239000000243 solution Substances 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 239000007924 injection Substances 0.000 claims description 5
- 238000002347 injection Methods 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 230000001954 sterilising effect Effects 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract description 11
- 239000008103 glucose Substances 0.000 abstract description 11
- 239000008280 blood Substances 0.000 abstract description 9
- 210000004369 blood Anatomy 0.000 abstract description 9
- 239000000463 material Substances 0.000 abstract description 6
- 230000007170 pathology Effects 0.000 abstract description 3
- 230000002093 peripheral effect Effects 0.000 abstract description 3
- 241000700159 Rattus Species 0.000 description 12
- 102000015336 Nerve Growth Factor Human genes 0.000 description 7
- 108010025020 Nerve Growth Factor Proteins 0.000 description 7
- 229940053128 nerve growth factor Drugs 0.000 description 7
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000037396 body weight Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 210000005036 nerve Anatomy 0.000 description 4
- 229940079593 drug Drugs 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 229940090044 injection Drugs 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000001953 sensory effect Effects 0.000 description 3
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010023126 Jaundice Diseases 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 2
- 230000036982 action potential Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 210000003423 ankle Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 230000007830 nerve conduction Effects 0.000 description 2
- 229960001052 streptozocin Drugs 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- 235000009051 Ambrosia paniculata var. peruviana Nutrition 0.000 description 1
- 241000272525 Anas platyrhynchos Species 0.000 description 1
- 235000003097 Artemisia absinthium Nutrition 0.000 description 1
- 240000001851 Artemisia dracunculus Species 0.000 description 1
- 235000017731 Artemisia dracunculus ssp. dracunculus Nutrition 0.000 description 1
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 1
- 235000017491 Bambusa tulda Nutrition 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 241001269238 Data Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 208000004454 Hyperalgesia Diseases 0.000 description 1
- 241000884394 Malva vein clearing virus Species 0.000 description 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 1
- 244000082204 Phyllostachys viridis Species 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 239000001138 artemisia absinthium Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 239000011425 bamboo Substances 0.000 description 1
- 239000010231 banlangen Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 230000005021 gait Effects 0.000 description 1
- 229940093181 glucose injection Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000009023 proprioceptive sensation Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 210000003497 sciatic nerve Anatomy 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 210000000453 second toe Anatomy 0.000 description 1
- 208000037118 sensory ataxia Diseases 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- GOLXNESZZPUPJE-UHFFFAOYSA-N spiromesifen Chemical compound CC1=CC(C)=CC(C)=C1C(C(O1)=O)=C(OC(=O)CC(C)(C)C)C11CCCC1 GOLXNESZZPUPJE-UHFFFAOYSA-N 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/074—Ganoderma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/19—Acanthaceae (Acanthus family)
- A61K36/195—Strobilanthes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
- A61K36/315—Isatis, e.g. Dyer's woad
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/744—Gardenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention provides application of the easypro treating hepatopathy in preparation treatment diabetic neuropathy and its complication medicine.The easypro treating hepatopathy is prepared by capillary extract, capejasmine extract, scutelloside, isatis root extract, Ganodenna Lucidum P.E and auxiliary material.The easypro treating hepatopathy can reduce blood glucose level, and it is obvious to increase NGF.Speed SNCV and MNCV, shorter latencies.It can be used for treating diabetes central neuropathy or diabete peripheral herve pathology.
Description
Invention field
The present invention relates to the new applications of easypro treating hepatopathy, in particular to relax proheparin preparation treatment diabetic neuropathy and
Application in complication medicine.
Background technique
Diabetic neuropathy (diabetic neuropathy) is one of most common chronic complicating diseases of diabetes, disease
Change can be involved nervous centralis and peripheral nerve.Disease incidence extends with the increase of age and the course of disease, seriously affects the life of patient
Quality.DNP damage can be involved sensory nerve, kinesitherapy nerve and vegetative nerve, but most commonly seen with sensory nerve.Clinical manifestation is
Subjective pain is violent, and pain such as cut sample burns sample, and with hyperalgia, combinable proprioception, seismesthesia are impaired, tendon reflex
Weaken or disappears；Sensory ataxia, instability of gait such as " duck step ", or just like cotton sample is stepped on is felt on foot；Distal limbs sense
Feel that decline such as " gloves ankle socks sample " is felt.
Treating hepatopathy relax by capillary extract, capejasmine extract, scutelloside, isatis root extract, Ganodenna Lucidum P.E and auxiliary
Material is prepared.With clearing heat and detoxicating, removing dampness through diuresis and removing jaundice, QI invigorating righting, liver protecting.It is all yellow for jaundice with damp-heat pathogen symptoms include appearance,
Sternal rib turgor, nausea and vomiting, dark urine is out of strength, receives difference, loose stool；Acute chronic viral hepatitis is shown in foregoing conditions person.Obtain piece
Agent fine powder loads capsule and recycles ethyl alcohol to get capsule and be concentrated into appropriate.Inventor is passing through lot of experiments discovery,
Easypro treating hepatopathy also has the function of certain treatment diabetic neuropathy and its complication medicine.
Summary of the invention
The object of the present invention is to provide easypro treating hepatopathies in preparation treatment diabetic neuropathy and its complication medicine
In application.
What the invention is realized by the following technical scheme: the treating hepatopathy that relaxes is in preparation treatment diabetic neuropathy and its simultaneously
Send out the application in disease drug.
Application above-mentioned, the complication include diabetes central neuropathy or diabete peripheral herve pathology.
In application above-mentioned, the easypro treating hepatopathy is mentioned by capillary extract, capejasmine extract, scutelloside, Radix Isatidis
Object, Ganodenna Lucidum P.E and auxiliary material is taken to be prepared.
In application above-mentioned, the easypro treating hepatopathy is prepared: take capillary extract, capejasmine extract, scutelloside,
One or more pharmaceutically acceptable auxiliary materials are added, according still further to pharmaceutical field in isatis root extract and Ganodenna Lucidum P.E
Conventional method is prepared into acceptable dosage form in field of medicaments.
In application above-mentioned, the dosage form includes ejection preparation or external preparation.
In application above-mentioned, the ejection preparation the preparation method comprises the following steps: take scutelloside add injection appropriate amount of water be suspended, add
10% sodium hydroxide solution makes to dissolve；Capillary extract, four taste of capejasmine extract, isatis root extract and Ganodenna Lucidum P.E are taken,
It is dissolved in water for injection respectively, mixes, add 0.2% active carbon, stir evenly, boil 15 minutes, filter, with 10% sodium hydroxide solution
PH value is adjusted to 7.5~8.0, injects water to specified amount, is filtered, encapsulating, sterilizing to get.
In order to make those of ordinary skill in the art better understand the present invention, come below by way of experiment and embodiment further
Illustrate purposes of the invention:
Experimental example pharmacological experiment study
1 materials and methods
1.1 drugs and reagent injection of the present invention, are prepared by embodiment 1.
Adult Wistar rats, half male and half female, 3 monthly ages, body are selected in 1.2 foundation, grouping and the medications for urinating sick animal model
Weight 200-250g.After Rat Fast 10h, streptozotocin (streptozotocin, STZ, Sigma company) 55ms/kg is given, is used
0.1mol/L sodium citrate buffer solution pH4.5 dilution, primary bosom intraperitoneal injection.48h later takes tail vein to be detected with blood glucose meter
Fasting blood-glucose > 16.7mmol/L, glucose in urine lasting masculin rat are set to diabetic animal models by blood glucose.It will be at mould male and female rat
It is randomly divided into each 8 of diabetes model (DM) group, treatment (TG) group, and the normal rat 8 to match with body rough bamboo mat, age is only used as
Normal control (NC) group, the citrate buffer solution of the corresponding volume of this group of rats by intraperitoneal injection.During the experiment, in equal conditions
After lower raising 8W, TG group gives easypro proheparin 15ml/kg, DM and NC and gives physiological saline, and abdominal cavity infuses 10d and takes rats at different levels execution
Material.
1.3 Testing index and method
1.3.1 general indicator (1) weight；(2) blood glucose.
1.3.2 after nerve conduction velocity measurement rat is anesthetized with ether successfully, electrode (stimulus wave is inserted into left incisura ischiadica
Width is 0.2ms), be inserted into recording electrode respectively between ankle (distal end) and left foot second toe (is respectively apart from stimulating electrode
3.5cm, 5.5cm) and computer is connected, use Denmark Cantata." electromyograph(EMG measurement, it records far and near end sciatic nerve and generates
The latent distance paid the phase, measure between two recording electrodes of action potential, and calculate sensory nerve conduction velocity (SNCV) and movement mind
Through the distance between conduction of velocity (MNCV) (m/s)=recording electrode/action potential incubation period.
1.3.3 the horizontal measurement of serum nerve growth factor (NGF) is according to kit (the limited public affairs of the gloomy male scientific and technological industry in Shanghai
Department, lot number 0412318) illustrate operate.
1.4 statistical method continuous datas indicate that the comparison of each group difference is examined using t with x ± s of growing sturdily.
2 results
The comparison that 2.1 each group rat body weights, blood glucose, nerve growth factor change is shown in Table 1.After diabetes model success, greatly
Mouse gradually appears more drinks, more foods, diuresis, and body weight increase is slowly or the symptom of weight loss.Compared with Normal group, model group
Blood glucose level is significantly raised, and weight is substantially less than control group (P < 0.01 *), and treatment group is close to normal group.With Normal group phase
Than the NGF of model group is substantially reduced, and treatment group is close to normal group.
The comparison of table 1 each group rat body weight, blood glucose, nerve growth factor
Compared with normal group: P < 0.01 *；#P < 0.05 compared with model group.
The comparison of 2.2 groups of rats SNCV and MVCV are shown in Table 2, table 3.Compared with Normal group, diabetic model group SNCV
And MNCV obviously slows down, prolongation of latency, wave amplitude reduces (P < 0.01).Treatment group and normal group are close.
The comparison in 2 each group rat SNCY incubation period, wave amplitude of table
Compared with normal group: P < 0.01 *；#P < 0.05 compared with model group.
The comparison of table 3 each group rat body weight, blood glucose, nerve growth factor
Compared with normal group: P < 0.01 *；#P < 0.05 compared with model group.
Conclusion: the easypro treating hepatopathy of the present invention can be treated to diabetic neuropathy, have prevention and treatment to make diabetic neuropathy
With.
Compared with prior art, easypro treating hepatopathy of the present invention can reduce blood glucose level, and it is obvious to increase NGF.Make SNCV
And MNCV is speeded, shorter latencies.It can be used for treating diabetes central neuropathy or diabete peripheral herve pathology.
Specific embodiment
Embodiment 1.
Formula: capillary extract 4g, capejasmine extract 3g, scutelloside 22g isatis root extract 5g and Ganodenna Lucidum P.E
3.5g。
Technique: it takes scutelloside that injection appropriate amount of water is added to be suspended, 10% sodium hydroxide solution is added to make to dissolve；Oriental wormwood is taken to extract
Object, four taste of capejasmine extract, isatis root extract and Ganodenna Lucidum P.E, are dissolved in water for injection respectively, mix, and add 0.2% to live
Property charcoal, stir evenly, boil 15 minutes, filter, with 10% sodium hydroxide solution adjust pH value to 7.5~8.0, inject water to rule
It is quantitative, filtration, encapsulating, sterilizing to get.
Usage and dosage: intravenous drip, a 10~20ml, with vein after 10% 250~500ml of glucose injection dilution
It instils, 1 times a day；Intramuscular injection can be used after remission instead, 2~4ml on the one 1 times a day, or follows the doctor's advice.
Points for attention: 1, pregnant woman and allergic constitution person are used with caution；
2, close observation medical fluid character before injecting, forbid when having muddy, precipitating, floccule using.
Specification: every dress 2ml, 10ml or 20ml
Storage: sealing is protected from light.
Validity period: 1.5 years.
Function with the major functions: diabetic neuropathy and its complication.
Claims (2)
1. application of the easypro treating hepatopathy in preparation treatment diabetic neuropathy and its complication medicine；
The easypro treating hepatopathy the preparation method comprises the following steps: formula: capillary extract 4g, capejasmine extract 3g, scutelloside 22g plate are blue
Root extract 5g and Ganodenna Lucidum P.E 3.5g；Technique: it takes scutelloside that injection appropriate amount of water is added to be suspended, adds 10% sodium hydroxide solution
Make to dissolve；Capillary extract, four taste of capejasmine extract, isatis root extract and Ganodenna Lucidum P.E are taken, respectively plus injection is water-soluble
Solution mixes, adds 0.2% active carbon, stir evenly, boil 15 minutes, filters, with 10% sodium hydroxide solution adjust pH value to 7.5~
8.0, inject water to specified amount, filter, encapsulating, sterilizing to get.
2. application as described in claim 1, it is characterised in that: the complication includes diabetes central neuropathy or sugar
Urinate sick peripheral neuropathy.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510906503.XA CN105412291B (en) | 2015-12-09 | 2015-12-09 | The proheparin that relaxes is preparing the application in treatment diabetic neuropathy and complication medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510906503.XA CN105412291B (en) | 2015-12-09 | 2015-12-09 | The proheparin that relaxes is preparing the application in treatment diabetic neuropathy and complication medicine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105412291A CN105412291A (en) | 2016-03-23 |
| CN105412291B true CN105412291B (en) | 2019-08-20 |
Family
ID=55491140
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510906503.XA Active CN105412291B (en) | 2015-12-09 | 2015-12-09 | The proheparin that relaxes is preparing the application in treatment diabetic neuropathy and complication medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105412291B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109793847A (en) * | 2019-04-09 | 2019-05-24 | 伍治明 | A kind of composite isatis root acupoint injection therapy liquid and preparation method thereof and application method |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1186091C (en) * | 2002-11-01 | 2005-01-26 | 贵州瑞和制药有限公司 | Chinese medicine injection and its production process |
| CN1813984B (en) * | 2005-12-14 | 2011-08-31 | 贵州瑞和制药有限公司 | Chinese medicine preparation for treating liver disease and preparing method |
| CN100558348C (en) * | 2006-06-16 | 2009-11-11 | 贵州益佰制药股份有限公司 | YINZHIHUANG ZHIJI and preparation method |
| CN103550281B (en) * | 2013-11-12 | 2015-11-18 | 庞会心 | The pharmaceutical composition of a kind of prevention and therapy diabetes and complication thereof and preparation thereof |
-
2015
- 2015-12-09 CN CN201510906503.XA patent/CN105412291B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN105412291A (en) | 2016-03-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103341135B (en) | Gel agent for treating arthralgia and preparing method thereof | |
| CN102872286B (en) | Traditional Chinese medicine composition for curing lumbar interveterbral disc protrusion and preparation method thereof | |
| CN1907316A (en) | Orthopaedics disease treating and preventing medicinal composition | |
| CN104398841A (en) | Traditional Chinese medicine preparation for treating cataract and glaucoma and preparation method of traditional Chinese medicine preparation | |
| CN105412291B (en) | The proheparin that relaxes is preparing the application in treatment diabetic neuropathy and complication medicine | |
| CN102846955A (en) | Chinese herbal medicine heightening insole | |
| CN102743734A (en) | Application of Tianlou Guizhi decoction in treatment of post-stroke spasm | |
| CN103549072B (en) | Vital energy-benefiting brain-boosting tea and preparation method thereof | |
| CN100563680C (en) | Chinese medicine preparation and the method for making and the application thereof of prevention and treatment intestinal adhesion after abdominal cavity operation | |
| CN100450494C (en) | Medicinal use of Aralia continentalis kitag | |
| CN102008539B (en) | Medicinal composition for treating diseases such as viral myocarditis and dilated cardiomyopathy and preparation process thereof | |
| CN105796927B (en) | A kind of Chinese medicine composition for treating blepharospasm | |
| CN101249236B (en) | Chinese and western medicine combined preparations for curing epileptic | |
| CN101045116B (en) | Traditional Chinese medicine for treating cholecystitis | |
| CN110051759A (en) | A kind of Chinese medicinal composition preparation and preparation method thereof for treating liver cancer | |
| CN103784825A (en) | Chuanhu gout mixture | |
| CN104223062B (en) | Root bark of Chinese wolf-berry health care oral liquid of a kind of reducing pressure and sugar and preparation method thereof | |
| CN102614375B (en) | Traditional Chinese medicine compound for tonifying kidney, strengthening yang and treating impotence and preparing method thereof | |
| CN116139212B (en) | Ocular hypotensive pharmaceutical composition, preparation method and application thereof | |
| CN106619816A (en) | Pharmaceutical composition for treating optic atrophy | |
| CN105497459A (en) | Traditional Chinese medicine preparation for treating woman leukorrheal diseases as well as preparation method and application of traditional Chinese medicine preparation | |
| CN102813745A (en) | Traditional Chinese medicine capsule for treating arrhythmia | |
| CN101274000B (en) | Medicine use of herb aralia elata seem | |
| CN106619975A (en) | Medicine injected at Zusanli acupoint for treating diabetic foot and preparation method of medicine | |
| CN1907315A (en) | Orthopaedics disease treating and preventing medicinal composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20190716 Address after: 551200 Camphor Rock, Gujiao Town, Longli County, Guizhou Province Applicant after: GUIZHOU RUIHE PHARMACEUTICAL Co.,Ltd. Address before: 551200 Wangchengpo, Guanshan Street Office, Longli County, Guizhou Province Applicant before: LONGLI PHARMACEUTICAL FACTORY, GUIZHOU RUIHE PHARMACEUTICAL CO.,LTD. |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Application of Shuganning in the preparation of drugs for diabetic neuropathy and complications Effective date of registration: 20200901 Granted publication date: 20190820 Pledgee: Agricultural Bank Chinese Limited by Share Ltd. Longli County branch Pledgor: GUIZHOU RUIHE PHARMACEUTICAL Co.,Ltd. Registration number: Y2020980005621 |
|
| PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20230925 Granted publication date: 20190820 Pledgee: Agricultural Bank Chinese Limited by Share Ltd. Longli County branch Pledgor: GUIZHOU RUIHE PHARMACEUTICAL Co.,Ltd. Registration number: Y2020980005621 |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Application of Shuganning in the preparation of drugs for the treatment of diabetes neuropathy and complications Effective date of registration: 20231011 Granted publication date: 20190820 Pledgee: Agricultural Bank Chinese Limited by Share Ltd. Longli County branch Pledgor: GUIZHOU RUIHE PHARMACEUTICAL Co.,Ltd. Registration number: Y2023520000056 |